Curated studies for research on COVID-19

31 Aug 2020

Curated COVID-19 data

NEBION continuously curates COVID-19 related gene expression studies and integrates them into GENEVESTIGATOR®. Using our unique tools, scientists can characterize this disease at the molecular level from multiple perspectives and compare results with thousands of other public datasets.

The following table describes high-quality human and mouse RNA-Seq and microarray studies that have been deeply curated and integrated into GENEVESTIGATOR® for research on COVID-19. Included in this collection are primarily studies investigating molecular changes associated with SARS-CoV-2 infections, as well as secondary studies investigating experimental COVID-19 treatments (repurposed) in the context of their original use.

To learn more about GENEVESTIGATOR and how you can analyze and visualize this data, visit the GENEVESTIGATOR website.

GENEVESTIGATOR ID Repository ID (s) Study Title Number of Samples
HS-03448 GSE100496/ GSE100504/ GSE100509/ GSE65574/ GSE79172/ GSE79218/ GSE79458/ GSE81909/ GSE86528/ GSE86529/ GSE86530 (part of GSE65575) Modeling Host Responses to Understand Severe Human Virus Infections 542
HS-03495 GSE150392 RNA-Seq of Human iPSC-cardiomyocytes infected with SARS-CoV-2 6
HS-03479 GSE150316 Spectrum of Viral Load and Host Response Seen in Autopsies of SARS-CoV-2 Infected Lungs 32
HS-03524 GSE151161 Blocking of the CD80/86 axis as a therapeutic approach to prevent progression to more severe forms of COVID-19 76
HS-03482 GSE149273 RV infections in asthmatics increase ACE2 expression and stimulate cytokine pathways implicated in COVID19 90
HS-03493 GSE151803 Identification of Lead Drug Candidates for COVID-19 based on Drug Screening Using Human Pluripotent Stem Cell-Derived Cells/Organoids 16
HS-03502 GSE148729 Gene expression profiling of SARS-CoV-1 & 2 infected human cell lines at bulk and single-cell level (total RNA) 14
HS-03490 GSE148729 Gene expression profiling of SARS-CoV-1 & 2 infected human cell lines at bulk and single-cell level (poly A) 70
HS-03525 GSE153970 Primary Human Airway Epithelial Cultures infected with SARS-CoV-2 6
HS-03527 GSE154613 Modulating the transcriptional landscape of SARS-CoV-2 as an effective method for developing antiviral compounds 63
HS-03480 GSE150819 Generation of human bronchial organoids for SARS-CoV-2 research. 18
HS-03481 GSE149312 Bulk RNA sequencing of SARS-CoV and SARS-CoV-2 infected human intestinal organoids. 22
HS-00702 GSE17400 Dynamic Innate Immune Responses of Human Bronchial Epithelial Cells against SARS-CoV and DOHV infection. 27
HS-03427 GSE47963 (superseries of GSE47960, GSE47961, GSE47962) SARS-CoV, SARS-dORF6 and SARS-BatSRBD infection of HAE cultures. 438
HS-03426 GSE45042 Cell host-response to infection with novel human coronavirus EMC predict potential antivirals and important differences with SARS-coronavirus 32
HS-03424 GSE56677 Cytokine stimulation systems approach demonstrates differences in innate and pro-inflammatory host responses between genetically distinct MERS-CoV isolates. 32
HS-03423 GSE37827 SCL006, icSARS CoV Urbani or icSARS Bat SRBD (spike receptor binding domain from the wild type strain Urbani to allow for infection of human and non-human primate cells) infections of the 2B4 clonal derivative of Calu-3 cells - Time course 87
HS-03422 GSE33267 SCL005: icSARS CoV Urbani or icSARS deltaORF6 infections of the 2B4 clonal derivative of Calu-3 cells - Time course 99
HS-03420 GSE147507 Transcriptional response to SARS-CoV-2 infection 67
HS-03375 GSE148817 (part of GSE148818) Cell-intrinsic differences between human tracheal epithelial cells from children and adults 6
HS-03244 GSE78068 Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study 209
HS-02837 GSE25160 Combination of peripheral blood gene expression profiles and clinical parameters predicts response for tocilizumab (anti-IL6) treatment in rheumatoid arthritis 26
HS-02781 GSE46293 (Superserie of GSE46280, GSE46282, GSE46283, GSE46292) Expression data of multiple sclerosis patients receiving Interferon-beta therapy 24
HS-01798 GSE56192 (part of GSE56189) Transcriptomic analysis of the Novel Middle East Respiratory Syndrome Coronavirus (Human, MRC5 cells) 25
HS-01477 GSE17183 Hepatic gene expression before and during interferon and ribavirin combination therapy 98
HS-01237 GSE45867 Effects of tocilizumab versus methotrexate therapy on gene expression profiles in the early rheumatoid arthrtis synovium 40
HS-00214 GSE7123 Gene profiling of responders and non-responders to antiviral therapies peg interferon and ribavirin against hepatitis C 341
MM-01639 GSE148829 SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues 65
MM-01685 GSE150847 Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment 6
MM-01637 GSE59185, GSE52920 Host responses contributing to the attenuation of severe acute respiratory syndrome coronaviruses missing E protein domains / GSE52920 18
MM-01636 GSE131936 Relative timing of type I interferon response and virus replication determines disease outcome during MERS-CoV infection 16
MM-01635 GSE146074 LY6E blocks coronavirus fusion and confers immune control of viral disease 36
MM-01632 GSE49262, GSE49263 SM012 - SARS MA15 wild type, and SARS deltaORF6 mutant virus infections of C57BL6 mice - A time course 75
MM-00498 GSE21583 Effects of ACE2 on BMPR2 mutation-mediated defects in gene expression 8
MM-01448 GSE84709 Expression data of Brain CD11b+ cells from WT and DP1 knockout mice infected with rJ2.2 7
MM-01140 GSE36016 Transcriptomic analysis of host response to mouse-adapted SARS virus in wild type, STAT1 -/-, and IFNAR1 -/- mouse genetic backgrounds 36
MM-01109 GSE51386 SM004 - SARS infection of C57BL6, TIMP1 and Serpine1 knock-out mice 38

Table: These human and mouse RNA-Seq and Microarray studies in GENEVESTIGATOR® investigate gene expression changes associated with SARS-CoV-2 and changes associated with experimental treatments of COVID-19.